<DOC>
	<DOCNO>NCT00635622</DOCNO>
	<brief_summary>This phase IIa clinical trial woman bacterial vaginosis . This study determine whether treatment vaginal lactobacillus combination antibiotic therapy ( metronidazole ) effective colonize vagina lactobacillus bacteria find normal vaginal flora .</brief_summary>
	<brief_title>Safety Efficacy Study Lactobacillus Administered Vaginally Women With Bacterial Vaginosis</brief_title>
	<detailed_description>Phase IIa randomize , double blind , placebo-controlled , clinical trial LACTIN-V 2 x 10^9 cfu/dose versus placebo , administer vaginally pre-filled applicator daily five consecutive day follow weekly dose 2 additional week initial standardized antibiotic treatment 0.75 % topical metronidazole ( MetroGel ) . A single site enroll 40 participant ( 30 randomize LACTIN-V 10 placebo ) . Colonization rate Lactobacillus crispatus CTV 05 assessed culture rep-PCR . Safety determine compare incidence adverse event serious adverse event LACTIN-V placebo group determine clinical symptom , physical examination , pelvic examination colposcopy laboratory measurement . Tolerability measure percentage subject discontinue study product use due overt adverse event percentage subject adhere complete dose schedule . Acceptability assess via standardized questionnaire focus group discussion .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Untreated BV ( asymptomatic symptomatic ) diagnose screen visit use Amsel criterion AND confirm laboratory use Nugent score system ( Nugent Score ≥ 7 ) . Otherwise healthy premenopausal woman 1840 year age date screening . Regular menstrual cycle ( 2135 day ) amenorrheic least 3 month due use long act progestin continuous use oral contraceptive . Subject willing insert prefilled vaginal applicator . Subject willing ask question personal medical health sexual history . Normal Pap smear collect screening visit . If subject 's Visit 0 Pap smear result follow , person ineligible participation : ASCUS ( atypical squamous cell undetermined significance ) , AGC ( atypical glandular cell ) , ASCH ( atypical squamous cell , r/o high grade lesion ) , LSIL ( low grade squamous intraepithelial lesion ) , HSIL ( high grade squamous intraepithelial lesion ) , adenocarcinoma situ , adenocarcinoma , squamous cell carcinoma situ , squamous cell carcinoma inadequate sample . Vaginal cervical anatomy opinion Investigator lend easily colposcopy . Capable read write English providing informed consent . Previous sexual experience include vaginal intercourse . Previous gynecological examination . Currently mutually monogamous sexual relationship sexually active . Agree sexually abstinent 72 hour prior Visit 1 ( enrollment ) Visit 2 ( Day 10 ) . Also , agree refrain intercourse 48 hour study product application Day 12 19 well 72 hour last study visit Day 28 . Agree abstain use intravaginal product ( i.e. , contraceptive cream , gel , foam , sponge , lubricant , douche , etc . ) throughout trial period , time screen Day 28 . Agree abstain use tampon throughout trial period , time screen Day 28 . Agree use adequate method birth control duration study avoid pregnancy . Acceptable method include history tubal ligation , male partner vasectomy , steroidal contraceptive ( oral , patch , injectable implantable ) , IUD ( Paragard Mirena ) , condoms abstinence . Subject must access function refrigerator . Urogenital infection screen within 21 day prior screen . This include urinary tract infection , Trichomonas vaginalis , Neisseria gonorrhoeae , Chlamydia trachomatis Treponema pallidum . Subjects may rescreened least 21 day respective antibiotic antifungal therapy complete . History recurrent genital herpes . Diagnosis N. gonorrhoeae , C. trachomatis , T. pallidum T. vaginalis two occasion six month prior screen . Pregnancy within 2 month last pregnancy ( subject urine pregnancy test prior enrollment ) . Lactation . Vaginal systemic antibiotic antifungal therapy within 21 day Screening visit within 30 day Enrollment visit . Investigational drug use within 30 day 10 halflives drug , whichever longer , enrollment visit . Planned investigational drug use participate study . Menopause . IUD insertion removal within last 3 month . Pelvic surgery within last 3 month . Cervical cryotherapy cervical laser within last 3 month . Use NuvaRing® within 3 day screen visit course study . New longacting treatment ( e.g . depot formulation include medroxyprogesterone acetate ( DMPA ) form hormonal birth control ) . Subjects may enrol stable ( &gt; 3months ) exist therapy determine Principal Investigator . Diabetes significant disease acute illness Investigator 's assessment could complicate evaluation . Known HIV infection positive HIV test screening . Immunosuppressive drug within 60 day . Previous participation L. crispatus CTV05 clinical study . Colposcopic finding enrollment visit involve significant deep disruption epithelium . Known allergy component LACTINV , significant drug allergy latex ( condom ) . Unavailable followup visit . History drug alcohol abuse . At enrollment , social medical condition , psychiatric illness , opinion Investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>BV</keyword>
	<keyword>UCSF</keyword>
	<keyword>SFGH</keyword>
</DOC>